NNVC vs. PMVP, VSTM, CLSD, CNTB, PRPH, LFVN, ASRT, ORMP, YS, and RLMD
Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include PMV Pharmaceuticals (PMVP), Verastem (VSTM), Clearside Biomedical (CLSD), Connect Biopharma (CNTB), ProPhase Labs (PRPH), LifeVantage (LFVN), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), YS Biopharma (YS), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
PMV Pharmaceuticals (NASDAQ:PMVP) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
PMV Pharmaceuticals received 21 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 60.00% of users gave PMV Pharmaceuticals an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
PMV Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NanoViricides is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
PMV Pharmaceuticals currently has a consensus price target of $5.75, suggesting a potential upside of 215.93%. Given NanoViricides' higher possible upside, research analysts clearly believe PMV Pharmaceuticals is more favorable than NanoViricides.
NanoViricides' return on equity of -29.14% beat PMV Pharmaceuticals' return on equity.
In the previous week, PMV Pharmaceuticals had 3 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for PMV Pharmaceuticals and 2 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.72 beat PMV Pharmaceuticals' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.
Summary
PMV Pharmaceuticals beats NanoViricides on 13 of the 15 factors compared between the two stocks.
Get NanoViricides News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoViricides Competitors List
Related Companies and Tools
